SNNAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SNNAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sienna Biopharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.00.
Sienna Biopharmaceuticals's EPS (Basic) for the three months ended in Sep. 2019 was $-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.00.
Sienna Biopharmaceuticals's EPS without NRI for the three months ended in Sep. 2019 was $-0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.02.
The historical data trend for Sienna Biopharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sienna Biopharmaceuticals Annual Data | |||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | |||||
Earnings per Share (Diluted) | -0.99 | -1.86 | -5.19 | -3.59 |
Sienna Biopharmaceuticals Quarterly Data | ||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -0.82 | -0.93 | -0.67 | -0.27 | -0.13 |
For the Biotechnology subindustry, Sienna Biopharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sienna Biopharmaceuticals's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Sienna Biopharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2018 is calculated as
Diluted Earnings Per Share (A: Dec. 2018 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-73.471 | - | 0) | / | 20.450 | |
= | -3.59 |
Sienna Biopharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2019 is calculated as
Diluted Earnings Per Share (Q: Sep. 2019 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-3.97 | - | 0) | / | 30.726 | |
= | -0.13 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Sienna Biopharmaceuticals (OTCPK:SNNAQ) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander Azoy | officer: Chief Financial Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Timothy K. Andrews | officer: General Counsel & Secretary | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Iii Frederick Beddingfield | director, officer: President & CEO | C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301 |
Paul F. Lizzul | officer: Chief Medical Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Diane Stroehmann | officer: See Remarks | 30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362 |
Dennis M Fenton | director | |
Todd Harris | director | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Kristina Burow | director, 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Robert J More | director | 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001 |
James M. Hindman | director | 2525 DUPONT DRIVE, IRVINE CA 92612 |
Keith R Leonard | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Arch Venture Partners Viii, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Fund Viii Overage, L.p. | 10 percent owner | C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Fund X Overage, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners X Overage, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By Marketwired Marketwired • 11-14-2019
By Marketwired Marketwired • 02-20-2019
By Marketwired Marketwired • 08-27-2018
By Marketwired Marketwired • 06-20-2019
By Marketwired Marketwired • 10-07-2019
By Marketwired Marketwired • 12-07-2018
By Marketwired Marketwired • 03-22-2019
By Marketwired Marketwired • 07-02-2018
By Marketwired Marketwired • 05-14-2019
By Marketwired Marketwired • 11-15-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.